Trial Outcomes & Findings for Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK) (NCT NCT03823794)
NCT ID: NCT03823794
Last Updated: 2025-06-06
Results Overview
Proportion of the arm/group receiving at least one prescription for emollients and soap substitutes.
Recruitment status
COMPLETED
Target enrollment
148166 participants
Primary outcome timeframe
Jan - Dec 2018 inclusive
Results posted on
2025-06-06
Participant Flow
Participant milestones
| Measure |
Active Atopic Dermatitis
People fulfilling the diagnostic criteria for active atopic dermatitis (AD) during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Overall Study
STARTED
|
148166
|
|
Overall Study
COMPLETED
|
148166
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Baseline characteristics by cohort
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Age, Customized
Age Group · <2
|
7230 Participants
n=5 Participants
|
|
Age, Customized
Age Group · 2-11
|
34074 Participants
n=5 Participants
|
|
Age, Customized
Age Group · 12-17
|
12476 Participants
n=5 Participants
|
|
Age, Customized
Age Group · 18-49
|
37995 Participants
n=5 Participants
|
|
Age, Customized
Age Group · >=50
|
56391 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
81357 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
66809 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · White
|
87717 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Asian
|
14980 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Black
|
5799 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Mixed
|
2808 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Other
|
1234 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Missing
|
35628 Participants
n=5 Participants
|
|
IMD quintile
1 (most deprived)
|
26454 Participants
n=5 Participants
|
|
IMD quintile
2
|
25520 Participants
n=5 Participants
|
|
IMD quintile
3
|
26445 Participants
n=5 Participants
|
|
IMD quintile
4
|
31426 Participants
n=5 Participants
|
|
IMD quintile
5 (least deprived)
|
36467 Participants
n=5 Participants
|
|
IMD quintile
Missing
|
1854 Participants
n=5 Participants
|
|
Rural-urban classification
Urban
|
117466 Participants
n=5 Participants
|
|
Rural-urban classification
Rural
|
29005 Participants
n=5 Participants
|
|
Rural-urban classification
Missing
|
1695 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for emollients and soap substitutes.
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes
|
76095 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for mild topical corticosteroids (atopic dermatitis related treatment)
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Mild Topical Corticosteroids (TCS)
|
40478 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for moderate topical corticosteroids (an atopic dermatitis related treatment)
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Moderate Topical Corticosteroids (TCS)
|
19575 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for potent topical corticosteroids (an atopic dermatitis related treatment)
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Potent Topical Corticosteroids (TCS)
|
34997 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for very potent topical corticosteroid (an atopic dermatitis related treatment)
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Very Potent Topical Corticosteroids (TCS)
|
6478 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for a topical Calcineurin Inhibitor (an atopic dermatitis related treatment)
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Topical Calcineurin Inhibitors (TCI)
|
2683 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for topical antimicrobials.
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Topical Antimicrobials
|
19378 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for antihistamin.
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Antihistamin
|
29041 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for Systemic immuno-modulatory therapy
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Systemic Immuno-modulatory Therapy
|
2785 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveProportion of the arm/group receiving at least one prescription for oral corticosteroids
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Prescription Rates for Atopic Dermatitis Related Treatments: Oral Corticosteroids
|
12087 Participants
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveSpecialist dermatology referral rate in 2018
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Specialist Referrals
|
5.0 Referrals per 100 person-years
Interval 4.9 to 5.1
|
PRIMARY outcome
Timeframe: Jan - Dec 2018 inclusiveAnnual rate of primary care consultations in 2018
Outcome measures
| Measure |
Active Atopic Dermatitis
n=148166 Participants
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018. Primary outcomes conducted within this single arm.
No intervention: Observational analysis of usual care only
|
|---|---|
|
Primary Care Referrals
|
112.0 Consultations per 100 person-years
Interval 111.5 to 112.6
|
Adverse Events
Active Atopic Dermatitis
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place